Jorge S Reis-Filho Selected Research

Nucleotides

1/2023	ctDNA-based detection of molecular residual disease in stage I-III non-small cell lung cancer patients treated with definitive radiotherapy.
1/2022	ATM Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications.
10/2014	Benchmarking mutation effect prediction algorithms using functionally validated cancer-related missense mutations.
2/2012	Whole genome sequencing of matched primary and metastatic acral melanomas.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jorge S Reis-Filho Research Topics

Disease

216	Neoplasms (Cancer) 05/2024 - 01/2002
144	Breast Neoplasms (Breast Cancer) 05/2024 - 06/2002
28	Carcinoma (Carcinomatosis) 01/2024 - 12/2002
16	Triple Negative Breast Neoplasms 04/2022 - 09/2008
14	Neoplasm Metastasis (Metastasis) 12/2023 - 09/2008
11	Lobular Carcinoma 02/2024 - 01/2005
9	Carcinogenesis 12/2023 - 01/2007
8	Ovarian Neoplasms (Ovarian Cancer) 01/2022 - 09/2011
8	Melanoma (Melanoma, Malignant) 10/2020 - 01/2003
8	Ductal Carcinoma 12/2014 - 04/2009
7	Disease Progression 04/2024 - 11/2012
7	Endometrial Neoplasms (Endometrial Cancer) 11/2023 - 10/2010
6	Lung Neoplasms (Lung Cancer) 12/2023 - 01/2014
5	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2022 - 12/2002
5	Adenocarcinoma 01/2022 - 01/2003
4	Acinar Cell Carcinoma 04/2024 - 10/2015
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2023 - 11/2022
4	Genomic Instability 10/2023 - 02/2008
4	Papillary Carcinoma 01/2020 - 02/2012
3	Colonic Neoplasms (Colon Cancer) 01/2023 - 01/2003
3	Pathologic Complete Response 01/2023 - 12/2010
3	Adenoid Cystic Carcinoma (Cylindroma) 08/2022 - 03/2010
3	Residual Neoplasm 01/2022 - 08/2015
3	Mucinous Adenocarcinoma (Mucinous Carcinoma) 01/2021 - 01/2019
3	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2021 - 04/2008
3	Metaplasia 01/2017 - 12/2002
3	Sarcoma (Soft Tissue Sarcoma) 01/2016 - 01/2005
3	Breast Carcinoma In Situ 04/2015 - 04/2002
3	Glioblastoma (Glioblastoma Multiforme) 01/2014 - 01/2003
3	Wilms Tumor (Wilm's Tumor) 04/2009 - 12/2006
2	Bites and Stings (Sting) 08/2023 - 01/2021
2	Ataxia Telangiectasia (Louis Bar Syndrome) 06/2023 - 01/2020
2	Neuroendocrine Carcinoma 04/2023 - 11/2009

Drug/Important Bio-Agent (IBA)

45	Estrogen ReceptorsIBA 10/2023 - 07/2005
41	DNA (Deoxyribonucleic Acid)IBA 10/2023 - 02/2006
37	Proteins (Proteins, Gene)FDA Link 11/2023 - 12/2002
30	Biomarkers (Surrogate Marker)IBA 05/2024 - 07/2008
30	Phenobarbital (Luminal)FDA Link 01/2020 - 05/2004
21	Progesterone Receptors (Progesterone Receptor)IBA 01/2023 - 03/2004
16	Cadherins (E-Cadherin)IBA 02/2024 - 04/2002
15	Hormones (Hormone)IBA 05/2024 - 07/2006
14	RNA (Ribonucleic Acid)IBA 01/2023 - 10/2011
13	Phosphotransferases (Kinase)IBA 06/2023 - 02/2007
10	ErbB Receptors (EGF Receptor)IBA 12/2023 - 01/2005
10	ParaffinIBA 01/2023 - 12/2002
10	AnthracyclinesIBA 01/2011 - 01/2007
9	Formaldehyde (Formol)FDA Link 01/2023 - 01/2005
9	AntibodiesIBA 09/2021 - 01/2005
8	Messenger RNA (mRNA)IBA 12/2023 - 12/2006
8	Trastuzumab (Herceptin)FDA Link 11/2023 - 05/2008
8	Monoclonal AntibodiesIBA 01/2021 - 01/2003
7	Poly(ADP-ribose) Polymerase InhibitorsIBA 03/2023 - 02/2008
7	Circulating Tumor DNAIBA 01/2023 - 10/2013
7	CateninsIBA 01/2021 - 10/2010
6	Cell-Free Nucleic AcidsIBA 01/2023 - 07/2013
6	AntigensIBA 01/2023 - 06/2007
6	Transcription Factors (Transcription Factor)IBA 01/2022 - 02/2011
6	Cyclin D1IBA 11/2010 - 04/2006
5	Lapatinib (GW572016)FDA Link 01/2023 - 09/2017
5	Keratins (Keratin)IBA 01/2020 - 08/2003
5	Indicators and Reagents (Reagents)IBA 04/2015 - 09/2004
4	NucleotidesIBA 01/2023 - 02/2012
4	MucinsIBA 01/2023 - 01/2019
4	human ERBB2 proteinIBA 01/2022 - 02/2011
4	Immune Checkpoint InhibitorsIBA 12/2021 - 01/2020
4	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2020 - 01/2003
4	Keratin-14 (Keratin 14)IBA 10/2013 - 08/2003
4	LigandsIBA 08/2011 - 01/2005
3	Eosine Yellowish-(YS) (Eosin)IBA 03/2023 - 01/2020
3	Hematoxylin (Haematoxylon)IBA 03/2023 - 01/2020
3	Protein Isoforms (Isoforms)IBA 08/2022 - 01/2002
3	B7-H1 AntigenIBA 01/2022 - 01/2021
3	Small Interfering RNA (siRNA)IBA 01/2022 - 01/2016
3	Mitogen-Activated Protein KinasesIBA 01/2022 - 03/2010
3	ChromatinIBA 10/2021 - 01/2002
3	Cyclin-Dependent Kinase 4IBA 01/2021 - 04/2006
3	Tumor Biomarkers (Tumor Markers)IBA 01/2021 - 08/2007
3	Aromatase InhibitorsIBA 10/2020 - 03/2015
3	VimentinIBA 01/2020 - 11/2005
3	PlatinumIBA 01/2020 - 11/2010
3	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2019 - 12/2009
3	ClaudinsIBA 01/2017 - 02/2012
3	Phosphatidylinositols (Phosphatidylinositol)IBA 05/2014 - 03/2010
3	Androgen Receptors (Androgen Receptor)IBA 12/2013 - 02/2012
3	OligonucleotidesIBA 02/2012 - 11/2009
3	Caveolin 1IBA 01/2012 - 01/2007
2	EnzymesIBA 05/2024 - 12/2023
2	Estrogen Receptor Modulators (Antiestrogen)IBA 05/2024 - 01/2020
2	Fluorouracil (Carac)FDA LinkGeneric 04/2024 - 01/2011
2	Immunoconjugates (Immunoconjugate)IBA 11/2023 - 01/2020
2	Ado-Trastuzumab EmtansineIBA 11/2023 - 01/2020
2	olaparibIBA 04/2023 - 09/2012
2	SynaptophysinIBA 01/2023 - 02/2017

Therapy/Procedure

81	Therapeutics 05/2024 - 01/2005
28	Drug Therapy (Chemotherapy) 01/2024 - 12/2006
15	Neoadjuvant Therapy 01/2023 - 06/2009
7	Radiotherapy 12/2023 - 01/2007
6	Immunotherapy 01/2022 - 01/2014
3	Chemoradiotherapy 01/2024 - 01/2021
3	Precision Medicine 10/2017 - 07/2013